Cargando…

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry

BACKGROUND: Since 2015, the European pulmonary hypertension guidelines recommend the use of combination therapy in most patients with pulmonary arterial hypertension (PAH). However, it is unclear to what extent this treatment strategy is adopted in clinical practice and if it is associated with impr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoeper, Marius M., Pausch, Christine, Grünig, Ekkehard, Staehler, Gerd, Huscher, Doerte, Pittrow, David, Olsson, Karen M., Vizza, Carmine Dario, Gall, Henning, Distler, Oliver, Opitz, Christian, Gibbs, J. Simon R., Delcroix, Marion, Ghofrani, H. Ardeschir, Rosenkranz, Stephan, Park, Da-Hee, Ewert, Ralf, Kaemmerer, Harald, Lange, Tobias J., Kabitz, Hans-Joachim, Skowasch, Dirk, Skride, Andris, Claussen, Martin, Behr, Juergen, Milger, Katrin, Halank, Michael, Wilkens, Heinrike, Seyfarth, Hans-Jürgen, Held, Matthias, Dumitrescu, Daniel, Tsangaris, Iraklis, Vonk-Noordegraaf, Anton, Ulrich, Silvia, Klose, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160392/ https://www.ncbi.nlm.nih.gov/pubmed/34675047 http://dx.doi.org/10.1183/13993003.02024-2021

Ejemplares similares

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
por: Hoeper, Marius M., et al.
Publicado: (2022)

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis
por: Schmidt, Kai-Helge, et al.
Publicado: (2023)

Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry
por: Kaemmerer, Harald, et al.
Publicado: (2020)

Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
por: Hoeper, Marius M, et al.
Publicado: (2022)

Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables
por: Pausch, Christine, et al.
Publicado: (2023)

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
por: Hoeper, Marius M., et al.
Publicado: (2015)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany
por: Kramm, Thorsten, et al.
Publicado: (2018)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2022)

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy
por: Knudsen, Lars, et al.
Publicado: (2011)

Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry
por: Said, Karim
Publicado: (2014)

Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study
por: Konstantinides, Stavros V., et al.
Publicado: (2016)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
por: Wissmüller, Max, et al.
Publicado: (2022)

Exercise training in pulmonary arterial hypertension associated with connective tissue diseases
por: Grünig, Ekkehard, et al.
Publicado: (2012)

Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients
por: Lerche, Marianne, et al.
Publicado: (2019)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
por: Theobald, Vivienne, et al.
Publicado: (2022)

Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial
por: Ehlken, Nicola, et al.
Publicado: (2016)

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study( )
por: Valerio, Luca, et al.
Publicado: (2022)

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
por: White, R. James, et al.
Publicado: (2019)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Exercise Training Improves Exercise Capacity and Quality of Life in Patients with Inoperable or Residual Chronic Thromboembolic Pulmonary Hypertension
por: Nagel, Christian, et al.
Publicado: (2012)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
por: Theobald, Vivienne, et al.
Publicado: (2023)

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
por: Cartin-Ceba, Rodrigo, et al.
Publicado: (2018)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries
por: Schweikert, Bernd, et al.
Publicado: (2014)

The original and two new derivative versions of the COMPERA 2.0 risk assessment model: useful tools for guiding balloon pulmonary angioplasty
por: Zhang, Yi, et al.
Publicado: (2022)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study
por: Brueckner, Claudia S, et al.
Publicado: (2010)

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study
por: Gall, Henning, et al.
Publicado: (2016)

Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study
por: Yogeswaran, Athiththan, et al.
Publicado: (2020)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
por: Stubbe, Beate, et al.
Publicado: (2021)

The molecular targets of approved treatments for pulmonary arterial hypertension
por: Humbert, Marc, et al.
Publicado: (2016)

Modulating cGMP to Treat Lung Diseases
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2009)

The role of combination therapy in managing pulmonary arterial hypertension
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2014)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

Cardiovocal Syndrome (Ortner's Syndrome) Associated with Chronic Thromboembolic Pulmonary Hypertension and Giant Pulmonary Artery Aneurysm: Case Report and Review of the Literature
por: Heikkinen, Jaakko, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sk62kb4ru3hiq2v8tartpad9sl